Cost Effectiveness Analysis Haloperidol-Chlorpromazine and Haloperidol-Risperidone for Treatment of Schizophrenia Patients at dr. H. Marzoeki Mahdi Hospital Bogor
Abstract
Schizophrenia is a disease that requires a long treatment time, this will have an impact on drug use and costs in the long term. Therefore it is necessary to find an alternative drug that is eff ective and effi cient by using pharmacoeconomics methods, that is cost-eff ectiveness analysis. The purpose of this study was to determine which of the two combination drugs was eff ective and effi cient for the treatment of schizophrenic patients in hospital Marzoeki Mahdi Bogor. This research method used cross sectional design, the sample size in this study was 90 schizophrenic patients obtained from patient medical records and data collected prospectively from dr. H. Marzoeki Mahdi in 2019. Samples were divided equally into two groups, one group received haloperidol - chlorpromazine and the second group received haloperidol - risperidone. The eff ectiveness parameter used in this study is the GAF (Global Assessment of Functioning) value. The results showed that the combination of haloperidol - risperidone was more eff ective than the combination of haloperidol - risperidone, this was evidenced by an increase in the patients GAF value by 95.5% (43 patients) with an average diff erence between the initial and fi nal GAF values of 6.89, while the combination of haloperidol - chlorpromazine amounted to 93.3% (42 patients) with an average diff erence between the initial and fi nal GAF values of 5.84. The ACER value of haloperidol - chlorpromazine is Rp. 6,587,753 and the ACER value for the haloperidol – risperidone combination is Rp. 6,148,897. In conclusion, the haloperidol - risperidone combination is more cost eff ective (p < 0.05) than the haloperidol - chlorpromazine combination.
References
keluarga dukung kesehatan jiwa masyarakat [Internet].
2016 [cited 2019 Jan 16]. P. 20–1. Available from:
http://www.depkes.go.id
2. Badan Penelitian Dan Pengembangan Kesehatan
Kementerian Kesehatan Republik Indonesia. Riset
Kesehatan Dasar 2013.
3. Kementerian Kesehatan Republik Indonesia. Potret
Sehat Indonesia dari Riskesdas 2018 p. 1–9. Available
from: www.depkes.go.id
4. Badan Penelitian Dan Pengembangan Kesehatan
Kementerian Kesehatan Republik Indonesia. Hasil
utama Riskesdas 2018.
5. Ayuningtyas D, Rayhani M. Analisis Situasi
Kesehatan Mental Pada Masyarakat Di Indonesia Dan
Strategi Penanggulangannya. Jurnal Ilmu Kesehatan
Masyarakat. 2018;9(1):1–10.
6. Meyer K, Pikalov A, Loebel A, Harbor P. Long-term
cost-eff ectiveness of atypical antipsychotics in the
treatment of adults with schizophrenia in the US.
Dovepress Clinical Outcomes Res. 2013;5:459–70.
7. Henry A. Nasrallah, Steven D. Targum. Rajiv
Tandon, Jeffrey S. Mccombs RR. Defining and
Measuring Clinical Eff ectiveness in the Treatment of
Schizophrenia. Vol. 56, Psychiatric Services. 2005.
P. 273–82.
8. Lally J, Maccabe JH. Antipsychotic medication
i n s ch iz o ph r en i a : a r ev i e w. B r Med B u l l.
2015;114(May):169–79.
9. Grover S, Chakrabarti S, Kulhara P, Avasthi A, Singh
OP, Singh B, et al. Clinical Practice Guidelines
for Management of Schizophrenia. Indian Journal
Psychiatry |. 2017;59:19–33.
10. Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura
M. Antipsychotic treatment for schizophrenia in
the maintenance phase : A systematic review of the
guidelines and algorithms. Schizophr Res. 2012;134(2–
3):219–25.
11. Aryani F, Sari O. Gambaran Pola Penggunaan
Antipsikotik Pada Pasen Skizofrenia Di Ruang Rawat
Inap Rumah Sakit Jiwa. J Manaj dan Pelayanan Farm.
2015;6, No. 1(p-ISSN: 2088-8139 e-ISSN: 2443-
2946):35–40.
12. Sinaga B. Skizofrenia dan Diagnosis Banding. Jakarta:
FKUI; 2007.
13. Pratiwi NLAG. Analisis Efektivitas Biaya Penggunaan
Kombinasi Antipsikotik Tipikal Dibandingkan dengan
Kombinasi Antipsikotik Tipikal dan Atipikal Pada
Pasien Skizofrenia Rawat Inap di RSJD Surakarta pada
Tahun 2016. Universitas Setia Budi Surakarta; 2017.
14. Byrne, M., Agerbo, E., Ewald, H., Eaton, W.W.,
Mortensen. PB. Parental Age and Risk of Schizophrenia.
Arch Gen Psychiatry. 2003;60(7):673–8.
15. Fahrul, Mukaddas A, Faustine I. Rasionalitas
Penggunaan Antipsikotik pada Pasien Skizofrenia
di Instalasi Rawat Inap Jiwa RSD Madani Provinsi
Sulawesi Tengah Periode Januari - April 2014. Online
Jurnal Natural Science. 2014;3(1):40–6.
16. David A. Buku Saku Psikiatri. Jakarta: Buku
Kedokteran EGC; 2004.
17. Sira I. Karakteristik Skizofrenia di Rumah Sakit
Khusus Alianyang Pontianak Periode 1 Januari – 31
Desember 2009. Naskah Publikasi Program Studi
Pendidikan Dokter. Fakultas Kedokteran Universitas
Tanjungpura, Pontianak. 2011;3–10.
18. Sadock B.J., Kaplan, H.I. Sinopsis psikiatri Jilid 1.
Jakarta: Binarupa Aksara; 2010.
19. Aryani F, Heriani D, Nofriyanti, Muharni S. Analisis
Efektifi tas Biaya dan Terapi Haloperidol-Klorpromazin
dan Risperidon-Klozapin pada Pasien Skizofrenia.
Pharmacy. 14, No. 01(p-ISSN 1693-3591, e-ISSN
2579-910X):98–107.
20. Peiró S, Gómez G, Navarro M, Guadarrama I,
Rejas J, Alvarez Díaz A, et al. Length of stay and
antipsychotic treatment costs of patients with acute
psychosis admitted to hospital in Spain - Description
and associated factors - The Psychosp study. Social
Psychiatry Epidemiology. 2004;39(7):507–13.
21. Fujimaki K, Takahashi T, Morinobu S. Association of
typical versus atypical antipsychotics with symptoms
and quality of life in schizophrenia. PLoS One.
2012;7(5).
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.
This licence applies to Author(s) and Public Reader means that the users mays :
- SHARE:
copy and redistribute the article in any medium or format - ADAPT:
remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication) - ALIKE:
If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original. - NO ADDITIONAL RESTRICTIONS:
You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
It does however mean that when you use it you must:
- ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
You may not:
- NONCOMMERCIAL: You may not use the article for commercial purposes.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Tools
